Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: Secondary analysis from a large clinical trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 11, 2014, Pages 1968-1974

  Baker, Joshua F ^a   Østergaard, Mikkel ^b,c   Emery, Paul ^d   Hsia, Elizabeth C ^a,e   Lu, Jiandong ^e   Baker, Daniel G ^e   Conaghan, Philip G ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Glostrup Hospital ^*  (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; GOLIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY;

ADULT; ARTHRITIS, RHEUMATOID; BONE MARROW DISEASES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DISEASE COURSE; DRUG COMBINATION; EARLY DIAGNOSIS; EDEMA; FEMALE; HUMAN; MALE; METACARPOPHALANGEAL JOINT; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SYNOVITIS; WRIST;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE MARROW DISEASES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; EDEMA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METACARPOPHALANGEAL JOINT; METHOTREXATE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SYNOVITIS; WRIST JOINT;

EID: 84881119287     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203444     Document Type: Article

References (14)

1. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheum 2003;30:1385-6.
2. Emery P, van der Heijde D, Ostergaard M, et al. Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:2126-30.
3. Ostergaard M, Hansen M, Stoltenberg M, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 2003;48:2128-31.
4. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57:350-6.
5. Haavardsholm EA, P PB, Østergaard M, et al. MRI-detected bone marrow edema is a predictor of subsequent radiographic progression in early rheumatoid arthritis (abstract). Ann Rheum Dis 2007;66(Suppl. II):94.
6. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69:1789-95.
7. Boyesen P, Haavardsholm EA, van der Heijde D, et al. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann Rheum Dis 2011;70:176-9.
8. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
9. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
10. Ostergaard M, Emery P, Conaghan PG, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011;63:3712-22.
11. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
12. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28.
13. Haavardsholm EA, Boyesen P, Ostergaard M, et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800.
14. Boyesen P, Haavardsholm EA, Ostergaard M, et al. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 2011;70:428-33.